Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system

被引:168
作者
Chattopadhyay, P.
Shekunov, B. Y.
Yim, D.
Cipolla, D.
Boyd, B.
Farr, S.
机构
[1] Ferro Corp, Pharmaceut Technol, Independence, OH 44131 USA
[2] Aradigm Corp, Hayward, CA 94545 USA
关键词
solid lipid nanoparticles (SLN); nanosuspensions; water-insoluble drugs; encapsulation; inhalers;
D O I
10.1016/j.addr.2007.04.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aims of the current work included: development of a new production method for nanoparticles of water-insoluble drugs in combination with lipids, characterization of the nanoparticles and development of lipid nanosuspension formulations, and investigation of the feasibility of delivering the nanosuspensions as aerosols for inhalation using Aradigm's AERx((R)) Single Dose Platform (SDP) with micron-sized nozzles and the all mechanical AERx Essence (TM) with sub-micron-sized nozzles. The continuous SFEE method was used for particle precipitation of solid lipid nanoparticles (SLN). The method allowed for production of stable particulate aqueous suspensions of a narrow size distribution, with a volume mean diameter below 30 nm (D99% cumulative volume below 100 nm). Thus the particle size obtained was significantly smaller than previously has been achieved by other techniques. The residual solvent content in the final suspension was consistently below 20 ppm. Drug loading values between 10-20% w/w drug were obtained for model compounds ketoprofen and indomethacin in formulation with lipids such as tripalmitin, tristearin and Gelucire 50/13. It was observed that the loading capacity achieved was higher than the thermodynamic limit of the solubility of the drugs in molten lipids. Lipid nanosuspension formulations were successfully aerosolized using both of the AERx systems. As measured by both cascade impactor and laser diffraction, the aerosol fine particle fraction (FPF) was comparable to drug solution formulations typically used in these devices; i.e., greater than 90% of the aerosol mass resided in particles less than 3.5 mu m aerodynamic diameter. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:444 / 453
页数:10
相关论文
共 29 条
[1]   Enhancement of topical delivery from biodegradable nanoparticles [J].
Alvarez-Román, R ;
Naik, A ;
Kalia, YN ;
Guy, RH ;
Fessi, H .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1818-1825
[2]   Effect of gender and device mouthpiece shape on bolus insulin aerosol delivery using the AERx pulmonary delivery system [J].
Boyd, B ;
Noymer, P ;
Liu, K ;
Okikawa, J ;
Hasegawa, D ;
Warren, S ;
Taylor, G ;
Ferguson, E ;
Schuster, J ;
Farr, S ;
Gonda, I .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1776-1782
[3]   Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles [J].
Cavalli, R ;
Caputo, O ;
Carlotti, ME ;
Trotta, M ;
Scarnecchia, C ;
Gasco, MR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 148 (01) :47-54
[4]  
CAVALLI R, 1996, EUR J PHARM BIOPHARM, V43, P110
[5]   Drug encapsulation using supercritical fluid extraction of emulsions [J].
Chattopadhyay, P ;
Huff, R ;
Shekunov, BY .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (03) :667-679
[6]  
CHOW AHL, 2004, SUPERCIRTICIAL FLUID, V138, P283
[7]  
Gasco M.R., 1997, PHARM TECHNOL EUR, V9, P52
[8]   The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers [J].
Kraft, WK ;
Steiger, B ;
Beussink, D ;
Quiring, JN ;
Fitzgerald, N ;
Greenberg, HE ;
Waldman, SA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (01) :67-72
[9]   Nanosizing: a formulation approach for poorly-water-soluble compounds [J].
Merisko-Liversidge, E ;
Liversidge, GG ;
Cooper, ER .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (02) :113-120
[10]   Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs [J].
MeriskoLiversidge, E ;
Sarpotdar, P ;
Bruno, J ;
Hajj, S ;
Wei, L ;
Peltier, N ;
Rake, J ;
Shaw, JM ;
Pugh, S ;
Polin, L ;
Jones, J ;
Corbett, T ;
Cooper, E ;
Liversidge, GG .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :272-278